title: Evaluation of DNA primase DnaG as a potential target for antibiotics.
abstract: Mycobacteria contain genes for several DNA-dependent RNA primases, including dnaG, which encodes an essential replication enzyme that has been proposed as a target for antituberculosis compounds. An in silico analysis revealed that mycobacteria also possess archaeo-eukaryotic superfamily primases (AEPs) of unknown function. Using a homologous recombination system, we obtained direct evidence that wild-type dnaG cannot be deleted from the chromosome of Mycobacterium smegmatis without disrupting viability, even in backgrounds in which mycobacterial AEPs are overexpressed. In contrast, single-deletion AEP mutants or mutants defective for all four identified M. smegmatis AEP genes did not exhibit growth defects under standard laboratory conditions. Deletion of native dnaG in M. smegmatis was tolerated only after the integration of an extra intact copy of the M. smegmatis or Mycobacterium tuberculosis dnaG gene, under the control of chemically inducible promoters, into the attB site of the chromosome. M. tuberculosis and M. smegmatis DnaG proteins were overproduced and purified, and their primase activities were confirmed using radioactive RNA synthesis assays. The enzymes appeared to be sensitive to known inhibitors (suramin and doxorubicin) of DnaG. Notably, M. smegmatis bacilli appeared to be sensitive to doxorubicin and resistant to suramin. The growth and survival of conditional mutant mycobacterial strains in which DnaG was significantly depleted were only slightly affected under standard laboratory conditions. Thus, although DnaG is essential for mycobacterial viability, only low levels of protein are required for growth. This suggests that very efficient inhibition of enzyme activity would be required for mycobacterial DnaG to be useful as an antibiotic target.
authors.affiliation: Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
authors.forename: Aneta
authors.initials: A
authors.lastname: Kuron
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Korycka-Machala
authors.forename: Anna
authors.initials: A
authors.lastname: Brzostek
authors.forename: Marcin
authors.initials: M
authors.lastname: Nowosielski
authors.forename: Aidan
authors.initials: A
authors.lastname: Doherty
authors.forename: Bozena
authors.initials: B
authors.lastname: Dziadek
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Dziadek
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D019915:DNA Primase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D005798:Genes, Bacterial / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects / Q000201:enzymology; D020102:Mycobacterium smegmatis / Q000187:drug effects / Q000201:enzymology; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology; D060888:Real-Time Polymerase Chain Reaction; D013498:Suramin / Q000494:pharmacology
chemical_list: D000995:Antitubercular Agents; D013498:Suramin; D004317:Doxorubicin; D019915:DNA Primase